Thank you, Chair.
My first question has to do with the new drug approval process.
I was at a forum at the Macdonald-Laurier Institute where there were a lot of stakeholders—industry, academia, policy people—talking about the PMPRB changes. They indicated that these will have huge unintended consequences. These will likely eliminate clinical trials in Canada, and companies will decide not to market new medicines to Canada. With this process, the changes are going to make it longer and more expensive for people to bring drugs here.
I see that there is money allocated in the estimates for changing this process.
Will the minister consider abandoning these changes based on the input from the industry, academia, policy, and other stakeholders?